19 research outputs found
Univariable and multivariable analyzes for loss of LTNP and HIV controller status.
<p>Univariable and multivariable analyzes for loss of LTNP and HIV controller status.</p
Loss of long-term non-progressor and HIV controller status over time in the French Hospital Database on HIV - ANRS CO4 - Fig 1
<p><b>Cumulative incidence of loss of LTNP (panel A) and HIV controller (panel B) status, treatment initiation and non AIDS deaths since 2005. A:</b> Long-term non-progressors (n = 171). <b>B:</b> HIV controllers (n = 72).</p
Characteristics of LTNP and HIC patients identified in 2005 who maintained or lost their status during follow-up.
<p>Characteristics of LTNP and HIC patients identified in 2005 who maintained or lost their status during follow-up.</p
Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France
<p><b>Background</b>: To evaluate the cost-effectiveness of an integrase inhibitor (INI), dolutegravir (DTG), in combination with abacavir (ABC)/lamivudine (3TC) in France, in treatment-naive (TN) HIV adult patients.</p> <p><b>Methods</b>: The ARAMIS microsimulation Markov model, evaluates costs and effects of DTG vs. first-line ARVs options including INIs (raltegravir, elvitegravir/c), protease inhibitors (PIs) (darunavir/r, atazanavir/r, lopinavir/r), non-nucleoside reverse transcriptase inhibitors (efavirenz and rilpivirine). Efficacy and safety data were derived from phase III studies and network meta-analysis. Treatment algorithms were based on French guidelines and experts opinion. Costs included routine HIV and opportunistic infection care, and death.</p> <p><b>Results</b>: The model showed the fixed-dose combination DTG/ABC/3TC was more effective than all other recommended regimens: patients stayed longer on first-line, and lived longer and healthier. With the exception of EFV, DTG/ABC/3TC was more efficacious and less costly compared to all strategies. The cost per QALY gained (ICER) for DTG compared to EFV was €6,939. DTG/ABC/3TC was more efficacious and less costly compared to INIs and PIs in all deterministic sensitivity analyses.</p> <p><b>Conclusion</b>: DTG/ABC/3TC was cost-effective in the management of HIV TN patients in France. These results are mainly explained by its lower price compared to other INIs and PIs, DTG’s superior efficacy and high barrier to resistance.</p
DSA—7 most influential parameters.
<p>AIDS: Acquired Immunodeficiency Syndrome; CD4: Cluster of Differentiation 4; DSA: Deterministic Sensitivity Analysis; ICER: Incremental Cost-Effectiveness Ratio; QALY: Quality Adjusted Life Year; OBT: Optimized Background Therapy.</p
Survival probability curve among the HIV infected patients cohort at the Bobo-Dioulasso day hospital between 2002 and 2012.
<p>Survival probability curve among the HIV infected patients cohort at the Bobo-Dioulasso day hospital between 2002 and 2012.</p
Influence diagram.
<p>AE: Adverse event; HIV: Human Immunodeficiency Virus; OI: Opportunistic Infection; QALYs: Quality Adjusted Life Years.</p
Survival probability curve according to antiretroviral therapy among the HIV infected patients cohort at the Bobo-Dioulasso day hospital between 2002 and 2012.
<p>(test de Breslow-Gehan-Wilcoxon P<10<sup>–4</sup>).</p
Distribution of ARV treatment lines given to patients (up to 31/12/2012).
<p>AZT: zidovudine; 3TC: lamivudine; EFV: efavirenz;</p><p>NEV: nevirapine; FTC: emtricitabine;</p><p>TDF: tenofovir disoproxil fumarate; LPV: lopinavir;</p><p>RTV: ritonavir; D4T: stavudine.</p><p>Distribution of ARV treatment lines given to patients (up to 31/12/2012).</p